Table 1 Inclusion/exclusion criteria of the study and control groups

Age (years)

20–40

20–40

Both ovaries present

Yes

Yes

Gonadotropin administration method

Redesigned GONAL-f pen injector allowing 12.5 IU dose increments

Other GONAL-f delivery methods^a

Without polycystic ovarian syndrome

Yes

Yes

BMI (kg/m²)

<30

<30

No use of urinary hMG/FSH or clomiphene citrate in same cycle

Yes

Yes

No contraindication to GONAL-f according to local SmPC

Yes

Yes